3 files

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

posted on 11.05.2022, 22:37 by Adis Journals on behalf of:, Lisa Beck, Mette Deleuran, Robert Bissonnette, Marjolein de Bruin-Weller, Ryszard Galus, Takeshi Nakahara, Seong Jun Seo, Faisal A. Khokhar, Jignesh Vakil, Jing Xiao, Ainara Rodriguez Marco, Noah A. Levit, John T. O’Malley, Arsalan Shabbir

© The authors, CC-BY-NC 2022

The above video abstract, graphical abstract and plain language summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite)..